Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 14, 2011; 17(42): 4643-4646
Published online Nov 14, 2011. doi: 10.3748/wjg.v17.i42.4643
Table 1 Rifaximin in inflammatory bowel disease
Ref.YearPatient (n)Study typeDose (mg)Duration (wk)Concomitant medicationOutcome
Crohn’s disease
Shafran et al[22]200529Open200 tid16VariousRemission up to 59%
Shafran et al[23]201068Open200 tid16Steroids (46%)Remission rate up to 65%
Prantera et al[24]200683Db RCT800 bid12NoneRemission rate > placebo
Prantera et al[25]2010402Db RCT400-1200 bid12Various (no steroids)Remission rate > placebo
Ulcerative colitis (also at 12 wk follow-up)
Guslandi et al[26]200630Open400 bid4MesalazineRemission rate 76%
Gionchetti et al[27]199928Db400 bid10 dSteroidsClinical improvement > placebo
Guslandi et al[28]20106Open, pilot400 od12S.boulardiiRemission maintained in 100%